Regencell Bioscience (NASDAQ:RGC) Trading Down 6.3% – Time to Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price fell 6.3% on Monday . The company traded as low as $5.50 and last traded at $5.5070. 74,501 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 323,320 shares. The stock had previously closed at $5.88.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Regencell Bioscience presently has an average rating of “Sell”.

Regencell Bioscience Stock Down 11.0%

The business’s fifty day moving average is $18.64 and its two-hundred day moving average is $24.79.

Regencell Bioscience (NASDAQ:RGC) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.00) earnings per share for the quarter.

Institutional Investors Weigh In On Regencell Bioscience

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Seven Fleet Capital Management LP bought a new position in Regencell Bioscience in the fourth quarter valued at about $92,000. Amundi bought a new stake in Regencell Bioscience during the 1st quarter worth about $219,000. Vident Advisory LLC raised its holdings in Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after purchasing an additional 11,866 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in Regencell Bioscience during the 4th quarter valued at about $275,000. Finally, Bank of America Corp DE lifted its position in Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after purchasing an additional 17,143 shares during the period. Institutional investors own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.